First Comprehensive Companion Diagnostic OK'd.

Abstract:

:The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

doi

10.1158/2159-8290.CD-NB2017-182

subject

Has Abstract

pub_date

2018-03-01 00:00:00

pages

OF4

issue

3

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-NB2017-182

journal_volume

8

pub_type

杂志文章
  • iRECIST Guideline Unveiled for Immunotherapies.

    abstract::The new iRECIST guideline-developed in consultation with academics, drug companies, and regulatory authorities-provides a standardized approach to assessing whether patients' disease improves, stays the same, or worsens in trials of immunotherapeutics, agents that can trigger different response patterns from other kin...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-NB2017-037

    authors:

    更新日期:2017-05-01 00:00:00

  • Novel molecule targets cytokinesis.

    abstract::Researchers have identified a new compound, OTS964, that blocks cytokinesis. Injections of the compound eliminated human lung tumors that had been transplanted into mice. Clinical trials of OTS964 may start next year. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2014-170

    authors:

    更新日期:2015-01-01 00:00:00

  • New Guideline on Managing Colorectal Cancer.

    abstract::A multidisciplinary panel of experts has issued guidelines that consolidate current evidence on testing for molecular biomarkers in colorectal cancer. The guidelines aim to standardize molecular testing for patients with colorectal cancer and help clinicians identify patients most likely to benefit from targeted treat...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-030

    authors:

    更新日期:2017-04-01 00:00:00

  • By the Numbers: New Biologic License Application Filings and Drug Approvals, 2007-2016.

    abstract::The FDA approved 22 novel drugs in 2016, down from 45 in 2015. Four of the new therapies are for cancer treatment, and two are for cancer diagnosis. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-003

    authors:

    更新日期:2017-02-01 00:00:00

  • Proteomics Sharpens Brain Tumor Genomic Analysis.

    abstract::A recent study integrating proteomic and genomic analyses uncovered unexpected similarities in some types of pediatric brain tumors, such as certain craniopharyngiomas and low-grade gliomas, suggesting potential treatments and more refined prognoses. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2020-119

    authors:

    更新日期:2021-01-07 00:00:00

  • Myelodysplastic Syndrome Splicing Factor Mutations Induce R-Loops.

    abstract::Mutations in SRSF2 and U2AF35 trigger replication stress and ATR activation via R-loop formation. ...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-RW2018-025

    authors:

    更新日期:2018-04-01 00:00:00

  • Drugs, diagnostic tests approved quickly.

    abstract::Accelerated review and greater understanding of tumor biology speed targeted treatments to patients. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-ND11-09

    authors: Rose S

    更新日期:2011-10-01 00:00:00

  • TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

    abstract:UNLABELLED:Targeted molecular therapy has yielded remarkable outcomes in certain cancers, but specific therapeutic targets remain elusive for many others. As a result of two independent RNA interference (RNAi) screens, we identified pathway dependence on a member of the Janus-activated kinase (JAK) tyrosine kinase fami...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-12-0504

    authors: Sanda T,Tyner JW,Gutierrez A,Ngo VN,Glover J,Chang BH,Yost A,Ma W,Fleischman AG,Zhou W,Yang Y,Kleppe M,Ahn Y,Tatarek J,Kelliher MA,Neuberg DS,Levine RL,Moriggl R,Müller M,Gray NS,Jamieson CH,Weng AP,Staudt LM

    更新日期:2013-05-01 00:00:00

  • Global Cost of Smoking Passes $1 Trillion.

    abstract::A new report from the World Health Organization and the NCI estimates that the worldwide cost of smoking-due to health problems and lost productivity-exceeds $1 trillion annually, with the biggest economic burden falling on low- and middle- income countries. That's because proven interventions, such as tax and price i...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-014

    authors:

    更新日期:2017-03-01 00:00:00

  • Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer.

    abstract::Oncogenic KRAS (KRAS*) is a key tumor maintenance gene in pancreatic ductal adenocarcinoma (PDAC), motivating pharmacologic targeting of KRAS* and its effectors. Here, we explored mechanisms involving the tumor microenvironment (TME) as a potential basis for resistance to targeting KRAS*. Using the inducible KrasG12D;...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-0597

    authors: Hou P,Kapoor A,Zhang Q,Li J,Wu CJ,Li J,Lan Z,Tang M,Ma X,Ackroyd JJ,Kalluri R,Zhang J,Jiang S,Spring DJ,Wang YA,DePinho RA

    更新日期:2020-07-01 00:00:00

  • Blood Monocyte Frequency May Be a Biomarker for Response to Anti-PD-1.

    abstract::CD14+CD16-HLA-DRhi monocyte frequency was linked to response to anti-PD-1 in patients with melanoma. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-RW2018-016

    authors:

    更新日期:2018-03-01 00:00:00

  • Metabolic Codependencies in the Tumor Microenvironment.

    abstract::Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell intrinsic mechanisms activate signal transduction compon...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-20-1211

    authors: Dey P,Kimmelman AC,DePinho RA

    更新日期:2021-01-27 00:00:00

  • 53BP1 regulates pRB via a lysine methylation-dependent interaction.

    abstract::53BP1 integrates pRB activity with the DNA damage response by binding to methylated K810. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-RW2014-164

    authors:

    更新日期:2014-09-01 00:00:00

  • Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

    abstract::Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide with no clinically confirmed oncogenic driver. Although preclinical studies implicate the FGF19 receptor FGFR4 in hepatocarcinogenesis, the dependence of human cancer on FGFR4 has not been demonstrated. Fisogatinib (BLU-554) is a potent an...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-0367

    authors: Hatlen MA,Schmidt-Kittler O,Sherwin CA,Rozsahegyi E,Rubin N,Sheets MP,Kim JL,Miduturu C,Bifulco N,Brooijmans N,Shi H,Guzi T,Boral A,Lengauer C,Dorsch M,Kim RD,Kang YK,Wolf BB,Hoeflich KP

    更新日期:2019-12-01 00:00:00

  • Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.

    abstract:UNLABELLED:As parallel advances in cancer biology and drug development continue to elevate the role of targeted therapies in oncology, the need for imaging biomarkers that systematically measure the biology associated with therapeutic intervention has become more urgent. Although the molecular imaging community has a c...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-12-0178

    authors: Evans MJ

    更新日期:2012-11-01 00:00:00

  • Resistance emerges to second-generation antiandrogens in prostate cancer.

    abstract::The appearance of a mutant androgen receptor, AR(F876L), in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-13-0405

    authors: Nelson WG,Yegnasubramanian S

    更新日期:2013-09-01 00:00:00

  • Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.

    abstract::An increasing number of anticancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Recent evidence suggests that the selection of patients whose tumors harbor specific genetic alterations identifies the subset of patients who are most likely to benefit from the use ...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-11-0110

    authors: MacConaill LE,Van Hummelen P,Meyerson M,Hahn WC

    更新日期:2011-09-01 00:00:00

  • Unfurling the Genetic Map of Sarcomas.

    abstract::An international team of researchers has uncovered multiple new germline mutations that may influence the development of sarcomas. Notably, they found that variants in several DNA damage sensing and repair genes contribute greatly to sarcoma risk, including BRCA2, ATM, ATR, and ERCC2. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2016-108

    authors:

    更新日期:2016-10-01 00:00:00

  • Combo Therapy for Lung Cancer Extends Survival.

    abstract::The PD-1 inhibitor pembrolizumab in combination with chemotherapy may be an effective therapy for patients with newly diagnosed advanced non-squamous non-small cell lung cancer. In a clinical trial, patients who received the combination had an estimated 12-month overall survival rate of 69.2%, compared with 49.4% in p...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2018-051

    authors:

    更新日期:2018-06-01 00:00:00

  • T-DM1 Combo Graduates from I-SPY 2.

    abstract::The combination of the antibody-drug conjugate ado-trastuzumab emtansine, or T-DM1, plus pertuzumab given prior to surgery outperformed standard therapy in women with HER2-positive breast cancer enrolled in the I-SPY 2 trial. The results, reported at the American Association for Cancer Research Annual Meeting 2016, su...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2016-048

    authors:

    更新日期:2016-06-01 00:00:00

  • Q&A: Mitchell Zeller on the FDA and tobacco.

    abstract::By law, the U.S. Food and Drug Administration has the authority, through its Center for Tobacco Products, to regulate the manufacture, marketing, and distribution of tobacco products. Its director, Mitchell Zeller, JD, talks about how the center, though its research, public education, and enforcement activities, aims ...

    journal_title:Cancer discovery

    pub_type: 面试

    doi:10.1158/2159-8290.CD-ND2013-028

    authors: Zeller M,Rose S

    更新日期:2014-01-01 00:00:00

  • Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.

    abstract::AKT inhibitors have promising activity in AKT1E17K-mutant estrogen receptor (ER)-positive metastatic breast cancer, but the natural history of this rare genomic subtype remains unknown. Utilizing AACR Project GENIE, an international clinicogenomic data-sharing consortium, we conducted a comparative analysis of clinica...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-1209

    authors: Smyth LM,Zhou Q,Nguyen B,Yu C,Lepisto EM,Arnedos M,Hasset MJ,Lenoue-Newton ML,Blauvelt N,Dogan S,Micheel CM,Wathoo C,Horlings H,Hudecek J,Gross BE,Kundra R,Sweeney SM,Gao J,Schultz N,Zarski A,Gardos SM,Lee J,S

    更新日期:2020-04-01 00:00:00

  • Tiragolumab Impresses in Multiple Trials.

    abstract::The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically significant results in multiple solid malignancies-most notably non-small cell lung cancer. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2020-063

    authors:

    更新日期:2020-08-01 00:00:00

  • AMG 510 First to Inhibit "Undruggable" KRAS.

    abstract::Amgen's novel small-molecule inhibitor AMG 510 has become the first drug to successfully target a KRAS mutation in patients, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. In a phase I trial, AMG 510 elicited partial responses in half of evaluable patients with KRASG1...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2019-073

    authors:

    更新日期:2019-08-01 00:00:00

  • IDO is a nodal pathogenic driver of lung cancer and metastasis development.

    abstract:UNLABELLED:Indoleamine 2,3-dioxygenase (IDO) enzyme inhibitors have entered clinical trials for cancer treatment based on preclinical studies, indicating that they can defeat immune escape and broadly enhance other therapeutic modalities. However, clear genetic evidence of the impact of IDO on tumorigenesis in physiolo...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-12-0014

    authors: Smith C,Chang MY,Parker KH,Beury DW,DuHadaway JB,Flick HE,Boulden J,Sutanto-Ward E,Soler AP,Laury-Kleintop LD,Mandik-Nayak L,Metz R,Ostrand-Rosenberg S,Prendergast GC,Muller AJ

    更新日期:2012-08-01 00:00:00

  • BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.

    abstract:: BRAF fusions and mutations are the most frequent genetic alterations in pediatric low-grade gliomas. The work from Wang and colleagues identifies an acquired secondary BRAF mutation that confers resistance to pharmacologic BRAF inhibition in a BRAFV600E glioma. The authors demonstrate that the mu...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-18-0784

    authors: Romano G,Kwong LN

    更新日期:2018-09-01 00:00:00

  • Genomic Screens Identify Genes That Regulate MHC-I Expression in DLBCL.

    abstract::MHC-I and MHC-II regulators in lymphomas, some of which had subtype or tumor specificity, were identified. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-178

    authors:

    更新日期:2020-12-11 00:00:00

  • Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

    abstract:UNLABELLED:Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using Next Generation RNA-sequencing and oligonucleotide arrays, we profiled 7 NEPC, 30 PCA, and 5 benign prostate tissue (BEN), and validated findings ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0130

    authors: Beltran H,Rickman DS,Park K,Chae SS,Sboner A,MacDonald TY,Wang Y,Sheikh KL,Terry S,Tagawa ST,Dhir R,Nelson JB,de la Taille A,Allory Y,Gerstein MB,Perner S,Pienta KJ,Chinnaiyan AM,Wang Y,Collins CC,Gleave ME,Demi

    更新日期:2011-11-01 00:00:00

  • Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

    abstract::Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alt...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-18-0275

    authors: Aguirre AJ,Nowak JA,Camarda ND,Moffitt RA,Ghazani AA,Hazar-Rethinam M,Raghavan S,Kim J,Brais LK,Ragon D,Welch MW,Reilly E,McCabe D,Marini L,Anderka K,Helvie K,Oliver N,Babic A,Da Silva A,Nadres B,Van Seventer EE,

    更新日期:2018-09-01 00:00:00

  • Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.

    abstract:UNLABELLED:Alterations in metabolic activity contribute to the proliferation and survival of cancer cells. We investigated the effect of siRNA-mediated gene silencing of 222 metabolic enzymes, transporters, and regulators on the survival of 3 metastatic prostate cancer cell lines and a nonmalignant prostate epithelial ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0234

    authors: Ros S,Santos CR,Moco S,Baenke F,Kelly G,Howell M,Zamboni N,Schulze A

    更新日期:2012-04-01 00:00:00